Company intelligence / Profile preview

Neukidney

Ownership: Private
Development stage: Preclinical

Overview

Neukidney has developed a proprietary conduit system designed to deliver cellular therapies directly into the kidneys. Preclinical studies have demonstrated safety in animal models. The technology aims to regenerate dying kidney tissue, potentially reducing the need for dialysis or transplantation. No human clinical results are available yet; regulatory approval has not been obtained.

Therapeutic areas: Nephrology
Modalities: Cellular therapies (including stem cells and non-stem cells)Platelet-based therapiesSmall molecule drug
Industry: Biotech

Drug pipeline

3 assets

QRX-3

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Neukidney.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neukidney.

Explore the full profile